Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Pharmanet Development Grp (MM) Charts. Click Here for more Pharmanet Development Grp (MM) Charts.](/p.php?pid=staticchart&s=N%5EPDGI&p=8&t=15)
PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of
drug development services, today announced that it will release its
fourth quarter and full year 2006 financial results on Thursday, March
1, 2007 before the market opens. Following the pre-market release, the
Company plans to host a conference call and webcast to review these
results at 8:30 a.m. Eastern Time.
Fourth Quarter and Full Year 2006 Earnings Conference Call:
When: Thursday, March 1, 2007 at 8:30 a.m. Eastern Time
Dial-in: (866) 713-8563 for U.S.
(617) 597-5311 for International
Pass code: 65023741
Dial-in Replay: (888) 286-8010 for U.S.
(617) 801-6888 for International
Pass code: 53682689
Available approximately two hours after the call
through Thursday, March 8, 2007
Webcast: Please visit www.pharmanet.com and select the
investor tab to access the webcast. The archived
webcast will be available for approximately thirty
(30) days following the conference call.
About PharmaNet Development Group, Inc.
Certain statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause or
contribute to such differences include, but are not limited to, industry
trends and information; whether adverse publicity relating to the Company’s
discontinued Florida operations causes clients to select competitors,
not only for early stage branded clinical trials but also for other
aspects of the Company’s business; its ability
to comply with the timeline agreed upon in the settlement reached with
the Miami-Dade County Unsafe Structures Board and any related fines or
expenses if we are unsuccessful complying with such timeline; the
associated costs and expenses with discontinuing the Company's
operations in Florida, including the potential costs of the demolition
of the Miami facility; the Company's ability to determine its impairment
charges and costs of discontinued operations; whether the Company will
achieve its estimated value for its Miami property; developments with
respect to the SEC's inquiry and securities class action lawsuits and
derivative lawsuits; the Company’s ability to
successfully achieve and manage the technical requirements of
specialized clinical trial services, while complying with applicable
rules and regulations; regulatory changes; changes affecting the
clinical research industry; a reduction of outsourcing by pharmaceutical
and biotechnology companies; the Company’s
ability to compete internationally in attracting clients in order to
develop additional business; the Company’s
evaluation of its backlog and the potential cancellation of contracts;
its ability to retain and recruit new employees; its clients' ability to
provide the drugs and medical devices used in its clinical trials; the
Company’s future stock price; its assessment
of its effective tax rate; the Company’s
financial guidance; our future effective tax rate; our anticipated 2006
capital expenditures; our 2006 costs of compliance of Section 404 of the
Sarbanes-Oxley Act; our ability to remediate our material weaknesses;
the impact of foreign currency transaction costs and the effectiveness
of any hedging strategies that we implement; and the national and
international economic climate as it affects drug development operations.
Further information can be found in the Company’s
risk factors contained in its Annual Report on Form 10-K for the year
ended December 31, 2005, which were originally filed as SFBC
International (NASDAQ: SFCC) and its most recent Quarterly Report on
Form 10-Q. The Company does not undertake to update the disclosures made
herein, and you are urged to read our filings with the Securities and
Exchange Commission.